The aim of this study is to ensure the superiority of Fimasartan/Amlodipine combination in
hypotensive effect after 8 weeks of treatment over Fimasartan monotherapy in patients with
hypertension who have no response to Fimasartan 60mg monotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd
Collaborators:
Asan Medical Center Chonnam National University Hospital Chungnam National University Dong-A University Hospital DongGuk University Gachon University Gil Medical Center Gangnam Severance Hospital Hanyang University Seoul Hospital Inje University Inje University Haeundai Paik Hospital Jeju National University Hospital Kangbuk Samsung Hospital Keimyung University Dongsan Medical Center Korea University Anam Hospital Korea University Guro Hospital Kyungpook National University Kyungpook National University Hospital Pusan National University Hospital Pusan National University Yangsan Hospital Seoul National University Bundang Hospital Seoul National University Hospital Severance Hospital The Catholic University of Korea Ulsan University Hospital Wonju Severance Christian Hospital